There are several studies that suggest that the use of G-CSF may increase the risk of secondary myeloid malignancies during follow-up (Relling et al, 2003; Hershman et al, 2007) however, evidence from NHL studies are lacking. Here, CSF3 is linked to non-Hodgkin lymphoma.